Unknown

Dataset Information

0

Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo.


ABSTRACT: Adenovirus (Ad)-mediated E2F-1 gene transfer induces apoptosis in cancer cells in vitro and in vivo, but clinical application of E2F-1 in cancer gene therapy remains controversial because of the oncogenic potential of E2F-1. This barrier can be circumvented by using the truncated form of the E2F-1 gene (E2Ftr) (amino acids 1 through 375), which lacks the E2F-1 transactivation domain and cell cycle-promoting effects.The authors constructed 3 adenoviral vectors that expressed E2Ftr under regulation of the tetracycline (Tet)-off system (AdTet-E2Ftr1, AdTet-E2Ftr2, and AdTet-E2Ftr3). These vectors were compared for E2Ftr expression and apoptosis induction in cancer cells and normal cells. E2Ftr antitumor activity in vivo also was assessed in a melanoma xenograft model.One of the 3 vectors, AdTet-E2Ftr3, had the highest E2Ftr protein expression levels, which were correlated with the greatest induction of apoptosis and inhibition of cancer cell growth. E2Ftr induced apoptosis in a variety of cancer cell lines independent of p53 status with little cytotoxicity in normal cell lines. In a mouse melanoma xenograft model, AdTet-E2Ftr3 exhibited an approximately 80% decrease in tumor size compared with controls in vivo.The current results indicated that AdTet-E2Ftr3 is a novel anticancer agent that has significant therapeutic activity in vitro and in vivo.

SUBMITTER: Gomez-Gutierrez JG 

PROVIDER: S-EPMC4425364 | biostudies-literature | 2010 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Adenovirus-mediated expression of truncated E2F-1 suppresses tumor growth in vitro and in vivo.

Gomez-Gutierrez Jorge G JG   Garcia-Garcia Aracely A   Hao Hongying H   Rao Xiao-Mei XM   Montes de Oca-Luna Roberto R   Zhou Heshan S HS   McMasters Kelly M KM  

Cancer 20100901 18


<h4>Background</h4>Adenovirus (Ad)-mediated E2F-1 gene transfer induces apoptosis in cancer cells in vitro and in vivo, but clinical application of E2F-1 in cancer gene therapy remains controversial because of the oncogenic potential of E2F-1. This barrier can be circumvented by using the truncated form of the E2F-1 gene (E2Ftr) (amino acids 1 through 375), which lacks the E2F-1 transactivation domain and cell cycle-promoting effects.<h4>Methods</h4>The authors constructed 3 adenoviral vectors t  ...[more]

Similar Datasets

| S-EPMC2703625 | biostudies-literature
| S-EPMC3021049 | biostudies-literature
| S-EPMC7025738 | biostudies-literature
| S-EPMC8072828 | biostudies-literature
| S-EPMC15140 | biostudies-literature
| S-EPMC9296534 | biostudies-literature
| S-EPMC3310701 | biostudies-literature
| S-EPMC5292956 | biostudies-literature
| S-EPMC10931526 | biostudies-literature
2021-05-05 | GSE163790 | GEO